A Calcagno1, S Nozza2, C Muss3, B M Celesia4, F Carli5, S Piconi6, G V De Socio7, A M Cattelan8, G Orofino9, D Ripamonti10, A Riva11, G Di Perri12. 1. Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy. andrea.calcagno@unito.it. 2. Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy. 3. Centro di Valutazione e Ricerca Gerontologica, University of Modena and Reggio Emilia, Modena, Italy. 4. Division of Infectious Diseases, Department of Clinical and Molecular Biomedicine, University of Catania, ARNAS Garibaldi, Catania, Italy. 5. Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Diseases Clinic, University of Modena and Reggio Emilia, Modena, Italy. 6. 1st Division of Infectious Diseases Unit, University of Milano, Ospedale L. Sacco, Milano, Italy. 7. Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy. 8. Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliera-Universitaria di Padova, Padova, Italy. 9. Unit of Infectious Diseases, "Divisione A", Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy. 10. Infectious Diseases Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. 11. 3rd Division of Infectious Diseases, University of Milano, Ospedale L. Sacco, Milano, Italy. 12. Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy.
Abstract
INTRODUCTION: After the introduction of highly active antiretroviral treatment, the course of HIV infection turned into a chronic disease and most of HIV-positive patients will soon be over 50 years old. MATERIAL AND METHODS: This paper reviews the multiple aspects that physicians have to face while taking care of HIV-positive ageing patients including the definitions of frailty and the prevalence and risk factors of concomitant diseases. From a therapeutic point of view pharmacokinetic changes and antiretroviral-specific toxicities associated with ageing are discussed; finally therapeutic approaches to frailty are reviewed both in HIV-positive and negative patients. CONCLUSION AND DISCUSSION: We conclude by suggesting that the combined use of drugs with the least toxicity potential and the promotion of healthy behaviours (including appropriate nutrition and exercise) might be the best practice for ageing HIV-positive subjects.
INTRODUCTION: After the introduction of highly active antiretroviral treatment, the course of HIV infection turned into a chronic disease and most of HIV-positive patients will soon be over 50 years old. MATERIAL AND METHODS: This paper reviews the multiple aspects that physicians have to face while taking care of HIV-positive ageing patients including the definitions of frailty and the prevalence and risk factors of concomitant diseases. From a therapeutic point of view pharmacokinetic changes and antiretroviral-specific toxicities associated with ageing are discussed; finally therapeutic approaches to frailty are reviewed both in HIV-positive and negative patients. CONCLUSION AND DISCUSSION: We conclude by suggesting that the combined use of drugs with the least toxicity potential and the promotion of healthy behaviours (including appropriate nutrition and exercise) might be the best practice for ageing HIV-positive subjects.
Authors: Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale Journal: J Virol Date: 2011-04-13 Impact factor: 5.103
Authors: A Calcagno; M C Alberione; A Romito; D Imperiale; V Ghisetti; S Audagnotto; F Lipani; S Raviolo; G Di Perri; S Bonora Journal: J Neurovirol Date: 2014-06-28 Impact factor: 2.643
Authors: Amy C Justice; Elizabeth Dombrowski; Joseph Conigliaro; Shawn L Fultz; Deborah Gibson; Tamra Madenwald; Joseph Goulet; Michael Simberkoff; Adeel A Butt; David Rimland; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Sheldon Brown; David A Leaf; Matthew B Goetz; Kendall Bryant Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Maria L Alcaide; Anita Parmigiani; Suresh Pallikkuth; Margaret Roach; Riccardo Freguja; Marina Della Negra; Hector Bolivar; Margaret A Fischl; Savita Pahwa Journal: PLoS One Date: 2013-05-28 Impact factor: 3.240
Authors: Giuseppe Vittorio De Socio; Elena Ricci; Giustino Parruti; Leonardo Calza; Paolo Maggi; Benedetto Maurizio Celesia; Giancarlo Orofino; Giordano Madeddu; Canio Martinelli; Barbara Menzaghi; Lucia Taramasso; Giovanni Penco; Laura Carenzi; Marco Franzetti; Paolo Bonfanti Journal: Infection Date: 2016-04-05 Impact factor: 3.553
Authors: Giuseppe Vittorio De Socio; Marta Pasqualini; Elena Ricci; Paolo Maggi; Giancarlo Orofino; Nicola Squillace; Barbara Menzaghi; Giordano Madeddu; Lucia Taramasso; Daniela Francisci; Paolo Bonfanti; Francesca Vichi; Marco dell'Omo; Luca Pieroni Journal: BMC Public Health Date: 2020-05-20 Impact factor: 3.295